AI assistant
DEXCOM INC — Director's Dealing 2024
Nov 18, 2024
30198_dirs_2024-11-18_6a1d58e6-fd3b-4f04-b34e-37b550c37443.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2024-11-15
Reporting Person: Sylvain Jereme M (EVP, Chief Financal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-15 | Common Stock | S | 3500 | $75.51 | Disposed | 80774 | Direct |
Footnotes
F1: On November 21, 2023, Mr. Sylvain adopted a 10b5-1 Plan which was amended on August 6, 2024. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above
were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 49,085 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 1,460 of which were granted on December 15, 2021 and shall vest through December 15, 2024.